Immunotech Biopharm Ltd

6978

KYG4721A1004

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:25 16/01/2026 pm IST			5-day change	1st Jan Change
2.780 ^HKD	-0.36%		+0.36%	-5.12%

09/12	Immunotech Biopharm Purchases 120 Million Yuan Worth of Structured Deposit Products	MT
08/12	Immunotech Biopharm subscribes to structured deposit products from Bank of China worth RMB120 million	RE

Immunotech Biopharm subscribes to structured deposit products from Bank of China worth RMB120 million

Published on 12/08/2025 at 09:02 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Immunotech Biopharm Ltd

09/12	Immunotech Biopharm Purchases 120 Million Yuan Worth of Structured Deposit Products	MT
08/12	Immunotech Biopharm subscribes to structured deposit products from Bank of China worth RMB120 million	RE
16/25/16	Immunotech Biopharm Ltd Announces Board and Audit Committee Changes, Effective October 16, 2025	CI
19/25/19	Immunotech Biopharm says underwriter agreed to underwrite up to 123.1 million rights shares	RE
19/25/19	HKEX says trading in shares of Immunotech Biopharm will be halted on Sept 19	RE
21/25/21	Immunotech Biopharm's H1 Loss Widens; Shares Rise 7%	MT
20/25/20	Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Immunotech Biopharm Ltd Announces Board Appointments, Effective 26 June 2025	CI
02/25/02	Immunotech Biopharm CEO/CTO Resigns	MT
30/25/30	Immunotech Biopharm Says Zhang Jian Appointed As Acting CEO	RE
30/25/30	Immunotech Biopharm Ltd Announces Chief Executive Officer Changes	CI
30/25/30	Immunotech Biopharm Ltd Announces the Resignation of Wang Yu as Executive Director and Chief Technology Officer, Effective 25 June 2025	CI
29/25/29	Immunotech Biopharm Ltd Auditor Raises 'Going Concern' Doubt	CI
25/25/25	Immunotech Biopharm Ltd Announces Board and Committee Changes	CI
01/25/01	Immunotech Biopharm's 2024 Loss Narrows	MT
31/25/31	Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
31/25/31	Immunotech Biopharm Says Conditional New Drug Application Of EAL Accepted By NMPA	RE
31/25/31	Immunotech Biopharm Ltd. Announces Conditional New Drug Application of EAL	CI
28/25/28	Immunotech Biopharm Ltd. Announces Recent Business Updates	CI
11/24/11	Immunotech's Leukemia Drug Gets Breakthrough Therapy Designation in China	MT
11/24/11	Immunotech Biopharm Ltd Announces CAR-T-19 Injection Receives Breakthrough Therapy Designation	CI
02/24/02	Immunotech Biopharm Ltd Announces Executive Changes	CI
23/24/23	Immunotech Biopharm Ltd(SEHK:6978) dropped from S&P Global BMI Index	CI
23/24/23	Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
29/24/29	Immunotech Biopharm CFO Steps Down	MT

Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.

Employees

173

Sector

Biotechnology & Medical Research

Calendar

20/03 - Q4 2025 Earnings Release (Projected)

More about the company